96 related articles for article (PubMed ID: 11888040)
1. Octreotide treatment of acromegaly during pregnancy.
Mikhail N
Mayo Clin Proc; 2002 Mar; 77(3):297-8. PubMed ID: 11888040
[No Abstract] [Full Text] [Related]
2. [Acromegaly associated with McCune-Albright syndrome].
Tóth M; Töke J; Kiss E; Bernád I; Miheller P; Szücs N; Rácz K
Orv Hetil; 2002 May; 143(19 Suppl):1070-3. PubMed ID: 12063863
[TBL] [Abstract][Full Text] [Related]
3. [Experience in treating acromegalic patients with long-acting octreotide].
Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
[TBL] [Abstract][Full Text] [Related]
4. Another case where bigger is not better.
Weber KT
Cardiovasc Res; 1997 Oct; 36(1):1-2. PubMed ID: 9415265
[No Abstract] [Full Text] [Related]
5. Pregnancy in acromegaly: successful therapeutic outcome.
Herman-Bonert V; Seliverstov M; Melmed S
J Clin Endocrinol Metab; 1998 Mar; 83(3):727-31. PubMed ID: 9506716
[No Abstract] [Full Text] [Related]
6. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.
Barakat S; Melmed S
Arch Intern Med; 1989 Jun; 149(6):1443-5. PubMed ID: 2730266
[TBL] [Abstract][Full Text] [Related]
7. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
8. Successful pregnancy in a woman with acromegaly treated with octreotide.
Neal JM
Endocr Pract; 2000; 6(2):148-50. PubMed ID: 11421531
[TBL] [Abstract][Full Text] [Related]
9. Scalp hair loss caused by octreotide in a patient with acromegaly: a case report.
Nakauchi Y; Kumon Y; Yamasaki H; Tahara K; Kurisaka M; Hashimoto K
Endocr J; 1995 Jun; 42(3):385-9. PubMed ID: 7670568
[TBL] [Abstract][Full Text] [Related]
10. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
11. [The treatment of acromegaly].
Beauregard H; Somma M; Rasio E; Serri O; Aris-Jilwan N; Comtois R; Long H; Abribat T; Boucher A; Hardy J
Union Med Can; 1993; 122(6):489-95. PubMed ID: 8303792
[TBL] [Abstract][Full Text] [Related]
12. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
[TBL] [Abstract][Full Text] [Related]
13. An audit of long-term octreotide therapy for acromegaly.
Cheung NW; Taylor L; Boyages SC
Aust N Z J Med; 1997 Feb; 27(1):12-8. PubMed ID: 9079247
[TBL] [Abstract][Full Text] [Related]
14. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study.
Colao A; Cappabianca P; Caron P; De Menis E; Farrall AJ; Gadelha MR; Hmissi A; Rees A; Reincke M; Safari M; T'Sjoen G; Bouterfa H; Cuneo RC
Clin Endocrinol (Oxf); 2009 May; 70(5):757-68. PubMed ID: 19178516
[TBL] [Abstract][Full Text] [Related]
15. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
16. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma.
Candrina R
Recenti Prog Med; 1994 Jan; 85(1):13-9. PubMed ID: 8184174
[TBL] [Abstract][Full Text] [Related]
17. Acromegaly and its treatment.
Lamberts SW
J Endocrinol; 1997 Oct; 155 Suppl 1():S49-51; discussion S67-71. PubMed ID: 9389995
[No Abstract] [Full Text] [Related]
18. Short-term continuous infusion of octreotide in acromegaly. Pharmacokinetics and prediction of the response to long-term treatment.
Timsit J; Chanson P; Harris AG; Grass P; Guillausseau PJ; Warnet A; Lubetzki J
Horm Metab Res; 1991 Jan; 23(1):48-9. PubMed ID: 2016081
[No Abstract] [Full Text] [Related]
19. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
Carlsen SM; Svartberg J; Schreiner T; Aanderud S; Johannesen O; Skeie S; Lund-Johansen M; Fougner SL; Bollerslev J;
Clin Endocrinol (Oxf); 2011 Jun; 74(6):736-43. PubMed ID: 21521254
[TBL] [Abstract][Full Text] [Related]
20. Successful pregnancy in a previously infertile woman treated with SMS-201-995 for acromegaly.
Landolt AM; Schmid J; Wimpfheimer C; Karlsson ER; Boerlin V
N Engl J Med; 1989 Mar; 320(10):671-2. PubMed ID: 2918882
[No Abstract] [Full Text] [Related]
[Next] [New Search]
